(Q47292862)

13 January 2018

title

Cautious optimism surrounds early clinical data for PD-1 blocker (English)

1 reference

13 January 2018

author name string

Cormac Sheridan

series ordinal

1

1 reference

13 January 2018

publication date

1 August 2012

1 reference

13 January 2018

published in

Nature Biotechnology

1 reference

13 January 2018

volume

30

1 reference

13 January 2018

issue

8

1 reference

13 January 2018

page(s)

729-730

1 reference

13 January 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNBT0812-729

Bristol-Myers Squibb swallows last of antibody pioneers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0812-729

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0812-729

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0812-729

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 January 2018

2 references

PubMed

https://pubmed.ncbi.nlm.nih.gov/22871693

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

https://api.crossref.org/works/10.1038%2FNBT0812-729

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NBT0812-729

1 reference

13 January 2018

1 reference

13 January 2018